$36.32
-0.21 (-0.56%)
Open$36.34
Previous Close$36.52
Day High$36.58
Day Low$35.00
52W High$33.99
52W Low$6.42
Volume—
Avg Volume928.3K
Market Cap1.67B
P/E Ratio—
EPS$-1.88
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
-48.4% upside
Current
$36.32
$36.32
Target
$18.74
$18.74
$15.89
$18.74 avg
$31.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 572.13M | 572.72M | 559.98M |
| Net Income | -99,921,707 | -80,567,499 | -92,627,690 |
| Profit Margin | -17.5% | -14.1% | -16.5% |
| EBITDA | -119,066,634 | -104,548,216 | -110,415,827 |
| Free Cash Flow | -98,412,160 | -88,741,836 | -111,480,768 |
| Rev Growth | +16.0% | -4.7% | +5.4% |
| Debt/Equity | 0.49 | 0.55 | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |